Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ITI-3000 |
Synonyms | |
Therapy Description |
ITI-3000 is a cancer vaccine comprised of a Merkel cell polyomavirus large T antigen (MCPyV-LT) linked to lysosomal-associated membrane protein 1 (LAMP1), which may lead to an enhanced antitumor immune response and inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 2052). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ITI-3000 | ITI 3000|ITI3000 | ITI-3000 is a cancer vaccine comprised of a Merkel cell polyomavirus large T antigen (MCPyV-LT) linked to lysosomal-associated membrane protein 1 (LAMP1), which may lead to an enhanced antitumor immune response and inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 2052). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05422781 | Phase I | ITI-3000 | Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC) | Completed | USA | 0 |